Table 1.
Patient baseline characteristics in relation to the results of indication biopsies
| Characteristic | All Patientsv (n=885) | C4d in PTCsa | ABMR Featuresb | ||||
|---|---|---|---|---|---|---|---|
| Yes (n=154) | No (n=671) | P Value | Yes (n=380) | No (n=494) | P Value | ||
| Recipient age (yr) | 52 (41–62) | 50 (40–60) | 52 (41–62) | 0.08 | 48 (38–58) | 55 (44–64) | <0.001 |
| Donor age (yr) | 50 (39–60) | 46 (36–59) | 51 (40–60) | 0.003 | 50 (39–59) | 51 (40–60) | 0.10 |
| Deceased donor transplants | 783 (89) | 140 (91) | 587 (88) | 0.25 | 335 (88) | 438 (88) | 0.82 |
| Prior allograft | 161(18) | 53 (34) | 100 (15) | <0.001 | 105 (27) | 55 (11) | <0.001 |
| ≥10% current CDC-PRA | 191 (22) | 65 (42) | 120 (18) | <0.001 | 113 (30) | 78 (16) | <0.001 |
| HLA mismatch (A, B, DR) | 3 (2–4) | 3 (2–4) | 3 (2–4) | 0.30 | 3 (2–4) | 3 (2–4) | 0.001 |
| Cold ischemia time (h) | 13 (8–19) | 13 (9–19) | 13 (8–19) | 0.12 | 13 (8–19) | 12 (8–18) | 0.21 |
| Initial immunosuppressive therapy | |||||||
| Cyclosporine | 656 (74) | 127 (83) | 484 (72) | 0.008 | 297 (78) | 351 (71) | 0.02 |
| Tacrolimus | 148 (17) | 20 (13) | 118 (18) | 0.17 | 58 (15) | 89 (18) | 0.27 |
| IL-2 receptor antibody | 161 (18) | 19 (12) | 130 (19) | 0.05 | 51 (13) | 108 (22) | 0.001 |
| Depleting antilymphocyte antibody | 122 (14) | 46 (30) | 68 (10) | <0.001 | 67 (18) | 53 (11) | 0.004 |
| Peritransplant IA | 66 (8) | 30 (20) | 33 (5) | <0.001 | 47 (12) | 19 (4) | <0.001 |
| mTOR inhibitor with or without CNI | 99 (11) | 8 (5) | 82 (12) | 0.01 | 33 (9) | 58 (12) | 0.15 |
Values are median (interquartile range) or number (percentage). For comparative analysis, Fisher exact and Mann–Whitney U tests were applied. CDC-PRA, complement-dependent cytotoxicity panel-reactive antibody; mTOR, mammalian target of rapamycin; IA, immunoadsorption; CNI, calcineurin inhibitor; PTCs, peritubular capillaries; ABMR, antibody-mediated rejection.
C4d staining results were available for 825 of the 885 included study patients. Patients with C4d scores > 0 were categorized as C4d+.
Biopsy material for a histomorphologic evaluation of ABMR-typical lesions (g, ptc, cg, v3 lesions, capillary microthrombi) was available for 874 of the 885 included study patients.